China New Product Diclofenac Gel - Epimedium Extract – Chenlv Detail:
Active ingredients: icariin, epinedoside A,noricarliin,I-cariresinol
CAS No.:489-32-7
Latin name: epimedium brevicornum maxim, epimedium sagittatum(sieb.et zucc.)maxim
Part used: leaf
Appearance: Brown and yellow powder
Test method: HPLC
Specifications:
icariin 10%,20%,50%,98%
Icariins 10%,20%,30%
Efficacy:
Epimedium is a traditional Chinese medicine supplement, which is used to make up the kidney of yang, strengthen the bone, remove the wind and wet wind, and it is used for anopsis, the disruptcy, rheumatism, rheumatism, numbness and contracture and menopausal hypertension. It can effectively inhibit staphylococcus and prevent aging. Epimedium is one of its active ingredients, which can effectively improve cardiac vascular system, adjust endocrine and improve endocrine. In addition, it is of particular concern that the Epimedium has anti-cancer effect and is regarded as the most potential anti-cancer drug.
Product packaging: 25kg/drum
Validity period: 24 months
Product detail pictures:
Related Product Guide:
We keep on with the theory of "quality first, provider initially, constant improvement and innovation to meet the customers" with the management and "zero defect, zero complaints" as the standard objective. To great our company, we deliver the merchandise using the fantastic excellent at the reasonable price for China New Product Diclofenac Gel - Epimedium Extract – Chenlv, The product will supply to all over the world, such as: Greece , Provence , Singapore , Why we can do these? Because: A, We are honest and reliable. Our products have high quality, attractive price, sufficient supply capacity and perfect service. B, Our geographical position has a big advantage . C, Various types: Welcome your inquiry, It will be highly appreciated.
By Victor from Slovakia - 2017.02.28 14:19
The customer service staff's attitude is very sincere and the reply is timely and very detailed, this is very helpful for our deal,thank you.
By Nydia from India - 2018.02.12 14:52